ProMIS Neurosciences, Inc. (PMN)
Summary
Ally Bridge Group NY LLC Increases Holdings in Promis Neurosciences $PMN
Ally Bridge Group NY LLC increased its position in Promis Neurosciences (NASDAQ: PMN) by 367.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,233,497 shares of the company's stock after buying an additional 4,899,069 shares during the quarter. Promis Neurosciences
ProMIS Neurosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 330 | $2,252 | $3,540.9 | $1,288.9 | 57.23% |
ProMIS Neurosciences, Inc. (PMN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProMIS Neurosciences, Inc. ever had a stock split?
ProMIS Neurosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Neil K. Warma CEO | NASDAQ (CM) Exchange | 74346M406 CUSIP |
| CA Country | 7 Employees | - Last Dividend | 28 Nov 2025 Last Split | 17 Jul 2007 IPO Date |
Overview
ProMIS Neurosciences, Inc. is a biotechnology company focused on discovering and developing antibody therapies and therapeutic vaccines for neurodegenerative diseases, and other conditions involving misfolded proteins. Based in Canada, ProMIS leverages its proprietary discovery platform that utilizes the ProMIS and Collective Coordinates algorithms. These tools are designed to predict novel targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Originally established as Amorfix Life Sciences Ltd., the company underwent a rebranding to ProMIS Neurosciences, Inc. in July 2015. Having been incorporated in 2004, it is headquartered in Toronto, Canada and continues to lead in the field of neurodegenerative diseases research by targeting the misfolded proteins involved in these conditions.
Products and Services
- PMN310
- PMN267
- PMN442
A leading monoclonal antibody (mAb) developed by ProMIS Neurosciences, PMN310 is specifically designed to target and neutralize toxic oligomers associated with Alzheimer's disease (AD). This approach aims at addressing disease progression at one of its critical molecular starting points, offering potential for highly effective therapy.
PMN267 is in development to target TDP-43 proteinopathies. Misfolding of the TDP-43 protein is implicated in a variety of neurodegenerative diseases, including certain forms of frontotemporal dementia and amyotrophic lateral sclerosis (ALS). By targeting the aberrant forms of TDP-43, PMN267 seeks to hinder the progression of these debilitating conditions.
Another monoclonal antibody in ProMIS Neurosciences’ pipeline is PMN442, which is designed to target toxic alpha-synuclein oligomers and seeding fibrils associated with Parkinson's disease and other synucleinopathies. The therapeutic strategy focuses on neutralizing these toxic species, which are central to the development and progression of Parkinson's disease and related disorders.
